Janumet Articles
Merck warned for not carrying out post-approval sitagliptin study
28 February 2012
Merck & Co rises 2.3% as it beats 4th quarter 2009 sales forecast, boosted by Schering-Plough
17 February 2010
One time gain triples Merck & Co’s 3rd quarter 2009 earnings, beating forecasts; EU clears S-P deal
23 October 2009
Merck & Co signs performance-based contract with CIGNA
24 April 2009
CHMP meeting sees good news for AZ, but not for Teva
24 April 2009
Merck & Co 1st-qtr profit slumps 57%
21 April 2009
EMEA's PDCO thumbs-up to eight PIPs
3 November 2008
Merck & Co gains EU appro for Janumet
28 July 2008
Vioxx costs see Merck & Co swing to $1.6B loss
4 February 2008
Merck & Co's 3rd-qtr 2007 sales jump 12%
29 October 2007
Merck & Co's 2nd-qtr 2007 EPS jumps 12%
30 July 2007
FDA clears Janumet for type 2 diabetes
9 April 2007
Stock Commentary - New York week to April 2
9 April 2007
Strong data on Merck & Co's Janumet
18 December 2006
Merck & Co announces trade name for MK-0431A
11 December 2006
Showing 1-24 of 24 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
